epigallocatechin gallate has been researched along with Brain Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, Y; Ji, S; Mi, Y; Tan, D; Zhou, Q | 1 |
| Duhamel, H; Griffioen, G; Pannecouque, C; Pellens, K; Van Damme, N; van Leuven, F; Wera, S; Winderickx, J; Zabrocki, P | 1 |
2 other study(ies) available for epigallocatechin gallate and Brain Diseases
| Article | Year |
|---|---|
Epigallocatechin-3-gallate attenuates cerebral cortex damage and promotes brain regeneration in acrylamide-treated rats.
Topics: Acrylamide; Animals; beta-Galactosidase; Brain Diseases; Brain-Derived Neurotrophic Factor; Camellia sinensis; Catechin; Cerebral Cortex; Cyclooxygenase 2; Humans; Male; Neuroprotective Agents; Nitric Oxide Synthase Type II; Plant Extracts; Rats; Rats, Sprague-Dawley; Regeneration; Tea | 2017 |
A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential.
Topics: alpha-Synuclein; Brain Diseases; Caspase Inhibitors; Caspases; Catechin; Flavonoids; Humans; Metals; Models, Biological; Molecular Structure; Neuroprotective Agents; Recombinant Fusion Proteins; Risk Factors; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2006 |